Co-Diagnostics Company Description

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.

The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.

It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.

In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings.

The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Co-Diagnostics, Inc.

Country	United States
Founded	2013
Industry	In Vitro and In Vivo Diagnostic Substances
Employees	155
CEO	Dwight Egan

Contact Details

Address: 2401 South Foothill Drive Salt Lake City, Utah 84109 United States
Phone	(801) 438-1036
Website	codiagnostics.com

Stock Details

Ticker Symbol	0A50
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2835

Key Executives

Name	Position
Dwight Egan	Chief Executive Officer
Brian Brown	Chief Financial Officer
David Nielsen	Chief Operating Officer
Andrew Benson	Head of Investor Relations